Grants Search Results

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on immunotherapy clinical trials, often their best hope for a cure.

This grant supports a solid tumor research coordinator to ensure that more solid tumor patients can be treated on early phase clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Imaging presents a powerful tool by visualizing individual cells and cellular processes in great detail. However, it remains very challenging to obtain this detailed cellular information for entire tumors and surrounding tissue, which will be key for improving our understanding of cancer progression. To fulfil this need, Dr. Rios and colleagues have developed unique and innovative imaging strategies that can visualize individual cells and their specific behavior in an entire tissue or tumor specimen. She is applying this advanced three-dimensional (3D) imaging to study the underlying mechanisms of childhood cancer. For instance, they have been able to identify new tumor cell subsets that are now being analyzed for their role in tumor progression. In addition, she is studying the specific behavior and underlying mechanisms that allow tumor cells to invade their surrounding tissue, a key contributing factor to tumor aggressiveness. By applying these imaging technologies to address these and other unanswered questions in pediatric oncology, Dr. Rios hopes to identify novel targets for treating childhood cancer. The St. Baldrick’s Robert J. Arceci Innovation Award is given in honor of the late Dr. Robert Arceci. A pioneer in the field, this award reflects Dr. Arceci’s values including creativity, collaboration, and commitment to early- to mid-career scientists.

Through this partnership with The Children's Cancer Foundation, proceeds from St. Baldrick's events in Hong Kong fund life-saving research in Hong Kong. The St. Baldrick's Foundation is proud to partner with the Children's Cancer Foundation and has been doing so since 2008.

This grant funded three projects. Project 1: A five-year study on Paediatric Hepatic International Tumour Trial (PHITT) in Hong Kong. Project 2: An extension of a parallel study with the Chinese children cancer group relapsed acute lymphoblastic leukemia 2017 Study (CCCG relapsed ALL 2017). Project 3: A New Clinical trial protocol for children with acute promyelocytic leukemia (APL) in Hong Kong.

This grant supports a Pediatric Neuro-Oncology Program Clinical Research Associate to ensure that more brain tumor patients can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Nurse to ensure that more kids can be treated on clinical trials, often their best hope for a cure. In the past, children diagnosed with cancer in the Rio Grande Valley had to travel to cities such as Houston or San Antonio to get state-or-the-art treatment through clinical trials. Physicians at the Vannie Cook Clinic in the Rio Grande Valley now have access to the most advanced trials and latest medications through Children's Oncology Group and other Texas-based clinical trials. This gives patients the opportunity to have the optimal outcome from their cancer therapy. More importantly, parents know that their child is getting the best care available, anywhere. That gives families hope that their child will live a long, healthy life.

This grant supports a research nurse coordinator to ensure that more Adolescent and Young Adult (AYA) patients can be treated on clinical trials, often their best hope for a cure.

This grant supports research associates to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Senior Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a research associate to ensure that more kids can be treated on early phase clinical trials, often their best hope for a cure.

This grant supports the Nurse Researchers in the UIC/Rush/Stroger COG Program to ensure more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports the creation of a Yale University Pediatric Hematology/Oncology tissue bank that will be used for current and future research projects involving the study of pediatric cancers. This repository will provide tissues for researchers seeking to study the biology, genetics and immunity of pediatric cancers. Establishment of this tissue bank will foster the ability of the institution to collaborate on more early phase clinical trials as well as to support discovery of new biomarkers to predict response to treatments.

This grant supports the Childhood Cancer Survivorship Program at Valley Children's Hospital, providing critical patient data for survivorship researchers.

Acute lymphoblastic leukemia (ALL) remains the most common cancer of children and young adults. Despite intensified treatments that achieved cure rates around 85%, there is a number of children who will relapse and succumb to therapy-resistant disease. One of the revolutions in the treatment of human cancer the last decade was immunotherapy, the ability of our own immune system to fight cancer. Unfortunately, despite its successes in a number of solid tumours, immunotherapy has not really impacted the treatment of leukemia, with the exception of CAR-T cell treatment of pediatric B-ALL. Indeed, some frequent types of pediatric ALL, and specifically T cell ALL (T-ALL) and its subtypes, have no immunotherapy treatment options. We believe that this is because we still don't understand how the cells of the immune system interact with the leukemia. Actually, researchers don't even know what type of immune cells are there available to fight the disease. Dr. Aifantis is applying a number of single cell techniques to create a map of the immune cells in the bone marrow of children with T-ALL. He is doing this at diagnosis of the disease, after treatment (remission) and when the children relapse. These studies will offer the first map of the immune system in pediatric ALL and will enable researchers to propose ways to activate the immune system to fight the tumour.

Thanks to remarkable scientific advances, over 80% of children with cancer will become long-term survivors, but most survivors experience long-term side effects of treatment. Our research has found that parents want early information about long-term side effects of treatment starting at diagnosis, but unfortunately most parents do not receive the information they need. In this project, Dr. Greenzang and colleagues are building a website to help parents understand the long-term effects of their treatment choices. They will then use the website with parents who are making new treatment decisions to evaluate whether parents find the website clear and useful, and to assess if using it can improve parents' understanding of medical information, help parents make decisions about treatment, and help prepare parents for their children's long-term care.

In the new era of personalized medicine, Ewing sarcoma still relies on decades-old chemotherapy options, where aggressive treatments are met with poor disease outcomes. Ewing sarcoma is a devastating disease that affects children and young adults age 5-16. Based on treatment outcome and patient qualities of life, Ewing sarcoma is in desperate need of research and development of new therapeutic options. One of the key observations of Ewing sarcoma made back in the 1930s is the accumulation of a large amount of glycogen. Glycogen is a sugar molecule that our body uses to store energy; only specific organs such as the liver and muscle are capable of producing glycogen. The ability of Ewing sarcoma tumors to store large amount of glycogen has been forgotten until now. Dr. Sun aims to understand the reason behind large glycogen accumulation in Ewing sarcoma and exploit the glycogen deposits as a possible drug target for the treatment of Ewing sarcoma. The successful completion of this project will bring new hope to this century-old disease and facilitate the development of the next generation of novel therapeutics specifically for Ewing sarcoma.

A portion of this grant is funded by and named for Julia's Legacy of Hope, a St. Baldrick's Hero Fund that honors her positive and courageous spirit and carries out Julia's last wish: "no child should have to go through what I have experienced". Diagnosed at age 16 with Ewing sarcoma, Julia fought cancer and survived only to be stricken in college with acute myeloid leukemia, a secondary cancer as a result of treatment. Through this Hero Fund, her family hopes to raise awareness and funds for childhood cancer research especially for Adolescent and Young Adult (AYA) patients.

This grant funds a medical school student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. Therapies that stimulate the immune system to target cancer cells are rapidly providing new and efficacious treatment options for pediatric patients with cancer. However, scientists are finding that solid tumors have evolved methods of inhibiting the immune system, minimizing the effects of these new therapies. One way of suppressing the immune system is through the upregulation of myeloid-derived suppressor cells. This study will help determine the prevalence and function of these cells in pediatric patients with solid tumors so that they can be specifically targeted to improve the efficacy of new immunotherapies.